Our Work in Gastroenterology
Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
Inflammatory Bowel Disorder, Crohn’s Disease, Ulcerative Colitis
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in gastroenterology and those who are close to them.
Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Wina – November 21, 2017
US Gastroenterologists May Thwart Uptake of New Biosimilars, Such as Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis, by Choosing an Alternative TNF-Inhibitor, Such as AbbVie’s Humira – August 29, 2017
Pfizer’s Inflectra, Takeda’s Entyvio, and Janssen’s Simponi Projected to Gain Ground in the Increasingly Competitive Ulcerative Colitis Market – July 7, 2017
Advances in Inflammatory Bowel Diseases 2017